|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Carcinoma, Non-Small-Cell Lung | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Carcinoma | |||||
| Lung Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Lung Diseases | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms by Site | |||||
| Neoplasms, Glandular and Epithelial | |||||
| Respiratory Tract Diseases | |||||
| Respiratory Tract Neoplasms | |||||
| Thoracic Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| Tarceva (erlotinib HCl, OSI-774 ) | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Erlotinib | |||||
| 6 | More general drug interventions related to this trial | ||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Protein Kinase Inhibitors | |||||
| 7 | Sponsors listed in this trial | ||||
| OSI Pharmaceuticals | |||||
| National Cancer Institute of Canada | |||||